Abbvie says Chief Scientific Officer John Leonard to retire
May 10 (Reuters) - AbbVie Inc's chief scientific officer will be retiring in the next few months and will be involved in the process of naming a successor, the pharmaceutical company said in a regulatory filing on Friday.
Chief Scientific Officer John M. Leonard, served in the Pharmaceuticals, Research and Development department for Abbott Laboratories before the branded pharmaceuticals business was spun off as AbbVie in November 2012. ()
Leonard who joined Abbott in 1992, was also the Senior Vice President for AbbVie received $5.5 million as compensation for 2012.
AbbVie, which posted a strong first quarter on strong sales of its Humira treatment for rheumatoid arthritis, expects to launch new treatments for hepatitis C by early 2015.
AbbVie's shares closed at $45.01 on Friday on the New York Stock Exchange.
- Air strike kills 15 civilians in Yemen by mistake: officials
- Pope attacks mega-salaries and wealth gap in peace message
- North Korea says Jang Song Thaek, uncle of leader Kim Jong Un, executed
- Probation for drunk Texas teen driver who killed four sparks backlash
- Atheists face death in 13 countries, global discrimination: study